Announced Wed, 15 Jul · 17:22 IST
Compliance certificate for dematerialization of securities – Q1 FY27
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.5%1-day move
₹7.48
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-5.5-5.6-3.2-4.4-4.8-5.5————
Up moveDown movePending
AI summary
Vista Pharmaceuticals submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. Its registrar, Aarthi Consultants, confirmed that all share certificates received for dematerialization were mutilated and cancelled within 15 days, and the depository was recorded as the registered owner. The securities are listed on BSE where original shares are listed. This is a routine procedural filing with no business or financial impact.
Likely market impact
No impact on shareholders or stock price; routine regulatory compliance for share dematerialization process.